Cardiodan® 1.25
Inotropic and Vasodilator for Congestive Heart Failure
Palatable tablets
Each 200 mg flavored tablet contains:
Pimobendan 1.25 mg; Excipients q.s.ad. 1 tablet
-Treatment of canine congestive heart failure (CHF) caused by dilated cardiomyopathy or valve regurgitation (mitral and/or tricuspid valve regurgitation).
-Treatment of dilated cardiomyopathy (CMD) in large breed dogs. When used in cases of CMD in large breed dogs, the time to onset of CHF or sudden death is significantly prolonged
and results in prolongation of the life span of the animal.
-Treatment of CMD in the preclinical stage (asymptomatic with increased end-systolic and end-diastolic diameters of the left ventricle), mainly in Doberman Pinschers after
echocardiographic diagnosis of heart disease.
-Treatment of dogs with myxomatous mitral valve disease (MVD) in the preclinical phase (asymptomatic with systolic mitral murmur and evidence of an enlarged heart) to delay the
onset of clinical symptoms of heart failure.
Orally. The dose is 0.25 mg/kg of body weight every twelve hours (morning and night) for a total daily administration of 0.5 mg/kg (in practice 1/2 tablet of
Cardiodan® 1.25 for every 2-5 kg every 12 hours). Should be administered one hour before meals.
Box x 10 tablets , Box x 30 tablets, Box x 60 tablets,
SENASA Registry: Reg. SENASA Peru: F.012.031.I.00022
Petmedica® is a division of Agrovet Market S.A.
Brochure
Insert
Shared
Whatsapp
This content is an informational reference and should not be considered as
recommendation of use.
